StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$2.95−0.05 (-1.67%)

Close on Nov 17, 2026Market cap $268.41MP/E –Yield –

SAB Biotherapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

SAB Biotherapeutics's price to book ratio was 1.2× on Nov 11, 2026, against 1.1× a year earlier. Over the last 5 years it ranged from 0.5× to 9.9×, with a median of 1.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.2×+0.1
2025Dec 31, 20251.1×+0.1
2024Dec 31, 20240.9×−3.2
2023Dec 29, 20234.2×+2.7
2022Dec 30, 20221.5×+0.2
2021Dec 31, 20211.3×–

More SAB Biotherapeutics figures

See a number that looks wrong?